ArticleBMC cancer2024

New evidence: Metformin unsuitable as routine adjuvant for breast cancer: a drug-target mendelian randomization analysis.

Jing-Xuan Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.